ESMO and EURACAN Demand European Policy Overhaul to Standardize Treatment for 650,000 Rare Cancer Patients

ESMO and EURACAN urge European policy action to mandate clinical guideline adherence for rare cancers, aiming to close survival gaps for 650,000 yearly patients.

By: AXL Media

Published: Mar 14, 2026, 5:31 AM EDT

Source: Information for this report was sourced from European Society for Medical Oncology (ESMO)

The Growing Crisis of Fragmented Rare Cancer Management

Despite accounting for nearly a quarter of all new cancer diagnoses in Europe, patients with rare malignancies continue to face a landscape of inconsistent care and varying survival outcomes. An analysis presented at the ESMO Sarcoma and Rare Cancers Congress 2026 highlights a critical disconnect between established evidence based guidelines and their actual application in clinical settings. With over 650,000 new cases reported annually, the call from medical experts emphasizes that the "rare" label applies to the specific disease type, not the total volume of patients affected. Experts argue that the current lack of standardization is a primary driver of the survival gap between rare and common cancers, necessitating a shift toward centralized and uniform treatment protocols.

Overcoming Evidence Scarcity Through Cross Border Collaboration

The inherent challenge in managing rare cancers lies in the low incidence rates that make randomized clinical trials difficult to conduct. This scarcity of data often leaves clinicians reliant on retrospective studies, registries, and expert consensus rather than high level clinical evidence. However, the European Reference Networks have begun to bridge this gap by facilitating cross border expertise and establishing the ESMO-EURACAN Clinical Practice Guidelines. These frameworks provide a vital roadmap for treatment in areas where local expertise may be lacking, yet their implementation remains highly variable across different European regions and clinical domains.

Survey Data Reveals Gaps in Guideline Utilization

A comprehensive survey conducted in late 2025 across 102 expert healthcare institutions in 25 countries revealed that while guideline uptake is strong for primary treatment decisions, it falters in other critical areas. More than 60% of respondents reported frequent use of these standards, but application remained markedly inconsistent for diagnostic procedures, follow up care, and research purposes. Prof. Jean-Yves Blay notes that these guidelines are often viewed narrowly as decision making tools rather than broader instruments for quality assurance and the standardization of best practices. This selective application suggests that while the "what" of treatment is often addressed, the "how" and "when" of the broader patient journey remain unstandardi...